The disclosure relates to binding assays that can measure the binding of ligands to a specific protein target in a micro-radiobinding assay. In particular, the present disclosure relates micro-radiobinding assays useful for low-abundance proteins, such as recombinant or tissue-derived proteins isolated from healthy or diseased, human donor samples.

Methods for selecting polypeptides or proteins having one or more desired properties from a library of sequences expressed in eukaryotic cells, including: encapsulating the cells by photopolymerization; solubilizing the encapsulated cells to produce semipermeable microcapsules; optionally contacting the cells and/or the microcapsules with one or more agents to facilitate detection of activity or function of polypeptides or proteins of interest; and selecting polypeptides or proteins of interest having one or more desired properties. Also provided are methods for encapsulating eukaryotic cells for use in the selection of polypeptides and proteins as described above.

Methods for selecting polypeptides or proteins having one or more desired properties from a library of sequences expressed in eukaryotic cells, including: encapsulating the cells by photopolymerization; solubilizing the encapsulated cells to produce semipermeable microcapsules; optionally contacting the cells and/or the microcapsules with one or more agents to facilitate detection of activity or function of polypeptides or proteins of interest; and selecting polypeptides or proteins of interest having one or more desired properties. Also provided are methods for encapsulating eukaryotic cells for use in the selection of polypeptides and proteins as described above.

The present disclosure describes technologies that permit sensitive detection of nucleic acids of interest (i.e., nucleic acids whose nucleotide sequence is or includes a target sequence). Among other things the disclosure provides a system comprising: a plurality of nucleic acid molecules having different nucleotide sequences; a set of ligation oligonucleotides, comprising: a first ligation oligonucleotide whose nucleotide sequence includes a templating element and a first target hybridization element; and a second ligation oligonucleotide whose nucleotide sequence includes a second target hybridization element and optionally a second templating element; wherein the target hybridization elements bind to different portions of a common target site, to form a gapped nucleic acid strand susceptible to ligation with a ligase to generate a ligated strand that is amenable to lateral flow assessment.

The present invention relates to a method for screening an antibody or antigen-binding fragment thereof by using cells bearing magnetic beads and, more particularly, to a method for screening an antibody binding specifically to an antigen protein or an antigen-binding fragment thereof, in which cells having biotinylated phospholipids in the cell membranes thereof and a streptavidin-magnetic bead complex fused to the surfaces thereof, and a magnetic-based system are utilized.

The present invention relates to a method for screening an antibody or antigen-binding fragment thereof by using cells bearing magnetic beads and, more particularly, to a method for screening an antibody binding specifically to an antigen protein or an antigen-binding fragment thereof, in which cells having biotinylated phospholipids in the cell membranes thereof and a streptavidin-magnetic bead complex fused to the surfaces thereof, and a magnetic-based system are utilized.

Provided are methods and compositions for the heterologous expression of a payload (e.g., DNA, RNA, protein) of interest in a target cell (e.g., cancer cell). In some cases payload delivery results in expression (e.g., by a cancer cell in vivo) of a secreted immune signal such as a cytokine, a plasma membrane-tethered affinity marker (thus resulting in an induced immune response), or a cytotoxic protein such as an apoptosis inducer (e.g., by a cancer cell in vivo). Payloads are delivered with a delivery vehicle and in some cases the delivery vehicle is a nanoparticle. In some cases a subject nanoparticle includes a targeting ligand for targeted delivery to a specific cell type/tissue type (e.g., a cancerous tissue/cell). In some embodiments, payload delivery is “personalized” in the sense that the delivery vehicle and/or payload can be designed based on patient-specific information.

Provided are methods and compositions for the heterologous expression of a payload (e.g., DNA, RNA, protein) of interest in a target cell (e.g., cancer cell). In some cases payload delivery results in expression (e.g., by a cancer cell in vivo) of a secreted immune signal such as a cytokine, a plasma membrane-tethered affinity marker (thus resulting in an induced immune response), or a cytotoxic protein such as an apoptosis inducer (e.g., by a cancer cell in vivo). Payloads are delivered with a delivery vehicle and in some cases the delivery vehicle is a nanoparticle. In some cases a subject nanoparticle includes a targeting ligand for targeted delivery to a specific cell type/tissue type (e.g., a cancerous tissue/cell). In some embodiments, payload delivery is “personalized” in the sense that the delivery vehicle and/or payload can be designed based on patient-specific information.

The present disclosure provides a method for screening cells, the method including a step of preparing a plurality of cells which are tagged with a first barcode nucleic acid associated with a test target and treated with the test target, a step of sorting the plurality of cells based on cellular phenotype using an imaging cell sorter, and a step of identifying the test target used to treat each cell using the first barcode nucleic acid as an indicator.

The present disclosure provides a method for screening cells, the method including a step of preparing a plurality of cells which are tagged with a first barcode nucleic acid associated with a test target and treated with the test target, a step of sorting the plurality of cells based on cellular phenotype using an imaging cell sorter, and a step of identifying the test target used to treat each cell using the first barcode nucleic acid as an indicator.